Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2013200489B2 - Methods for use in modulating miR-122a - Google Patents
[go: Go Back, main page]

AU2013200489B2 - Methods for use in modulating miR-122a - Google Patents

Methods for use in modulating miR-122a

Info

Publication number
AU2013200489B2
AU2013200489B2 AU2013200489A AU2013200489A AU2013200489B2 AU 2013200489 B2 AU2013200489 B2 AU 2013200489B2 AU 2013200489 A AU2013200489 A AU 2013200489A AU 2013200489 A AU2013200489 A AU 2013200489A AU 2013200489 B2 AU2013200489 B2 AU 2013200489B2
Authority
AU
Australia
Prior art keywords
mir
methods
activity
elevated serum
oligomeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013200489A
Other versions
AU2013200489A1 (en
Inventor
Sanjay Bhanot
Christine Esau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regulus Therapeutics Inc
Original Assignee
Regulus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011254085A external-priority patent/AU2011254085B2/en
Application filed by Regulus Therapeutics Inc filed Critical Regulus Therapeutics Inc
Priority to AU2013200489A priority Critical patent/AU2013200489B2/en
Publication of AU2013200489A1 publication Critical patent/AU2013200489A1/en
Application granted granted Critical
Publication of AU2013200489B2 publication Critical patent/AU2013200489B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

METHODS FOR USE IN MODULATING MIR-122A Methods are provided for the treatment of cardiovascular or metabolic diseases characterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Further provided are methods for reducing hepatic steatosis or liver tissue triglyceride accumulation through the administration of an oligomeric compound which modulates the levels or activity of miR-122a. Such methods employ oligomeric compounds which hybridize with or sterically interfere with nucleic acid molecules comprising or encoding miR-122a. Such oligomeric compounds may include one or more modifications thereon, which may improve the activity, stability, or nuclease resistance of the oligomeric compound. These modified oligomeric compounds are used as single compounds or in compositions, including pharmaceutical compositions, to modulate or mimic the targeted nucleic acid comprising or encoding miR-122a.
AU2013200489A 2005-08-29 2013-01-31 Methods for use in modulating miR-122a Ceased AU2013200489B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013200489A AU2013200489B2 (en) 2005-08-29 2013-01-31 Methods for use in modulating miR-122a

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60/712,211 2005-08-29
US60/731,377 2005-10-28
US60/771,592 2006-02-07
AU2011254085A AU2011254085B2 (en) 2005-08-29 2011-12-15 Methods for use in modulating miR-122a
AU2013200489A AU2013200489B2 (en) 2005-08-29 2013-01-31 Methods for use in modulating miR-122a

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2011254085A Division AU2011254085B2 (en) 2005-08-29 2011-12-15 Methods for use in modulating miR-122a

Publications (2)

Publication Number Publication Date
AU2013200489A1 AU2013200489A1 (en) 2013-02-21
AU2013200489B2 true AU2013200489B2 (en) 2015-09-17

Family

ID=47722591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013200489A Ceased AU2013200489B2 (en) 2005-08-29 2013-01-31 Methods for use in modulating miR-122a

Country Status (1)

Country Link
AU (1) AU2013200489B2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas

Also Published As

Publication number Publication date
AU2013200489A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
WO2007027775A3 (en) Methods for use in modulating mir-122a
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2008073919A3 (en) Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2009046141A3 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
WO2006026485A3 (en) Modulation of hif1-beta expression
MX2010009654A (en) Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders.
WO2007144394A3 (en) Pharmaceutical use of substituted piperidine carboxamides
WO2008073920A3 (en) Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2004093783A3 (en) Modulation of apolipoprotein c-iii expression
EP2349279A4 (en) ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
WO2009070805A3 (en) Mir-124 regulated genes and pathways as targets for therapeutic intervention
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
WO2008062276A8 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
WO2009010974A3 (en) Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
WO2008085797A3 (en) miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
WO2010007482A3 (en) Thiazole derivatives as stearoyl coa desaturase inhibitors
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
WO2011031063A3 (en) Composition for preventing or treating metabolic disorders, containing the anti-4-1bb antibody
WO2005071080A3 (en) Modulation of glucocorticoid receptor expression
WO2006078659A3 (en) Stable prostaglandin-containing compositions
WO2008036718A3 (en) Mir-143 regulated genes and pathways as targets for therapeutic intervention
ATE529404T1 (en) PHENOXYACETIC ACIDS AS PPAR-DELTA ACTIVATORS
WO2012145520A3 (en) Carbon monoxide releasing molecules and uses thereof
WO2009027527A3 (en) Rna antagonist compounds for the modulation of fabp4/ap2

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired